Company News & Publications

Breaking News

SAN FRANCISCO, CA, January 12, 2012
Druggability Technologies Announces Financial Investment by SPCH

Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, announced today that it has completed an initial round of financing totaling $4,000,000.

Upcoming event

March 1-2, 2012, Krems, Austria
BioNanoMed 2012

March 19-22, 2012, Istambul, Turkey
World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

April 30 - May 1, 2012, San Diego, USA
Drug Delivery and Formulation America 2012

June 18-21, 2012, Boston, USA
Bio International Convention 2012

July 15-17, 2012, Amsterdam, The Netherlands
Colloids and Nanomedicine 2012

Latest events

January 16-18, 2012, Berlin, Germany
Drug Delivery and Formulation Summit 2012

October 31-November 2, 2011, Dusseldorf, Germany
BIO Europe

October 4-5, 2011, Boston, USA
Partnership Opportunities in Drug Delivery

May 30th - 1st June, 2011, Budapest, Hungary
EuroNanoForum

April 27th-28th, 2011, San Diego, CA, USA
DDF America 2011

January 17th-18th, 2011, Berlin, Germany
World Drug Delivery and Formulation 2011

November 15-17, 2010, Munich, German
BIO - Europe 2010

August 22 – 26, 2010, Boston, Massachusetts, USA
Fall 2010 National Meeting & Exposition

August 24-27, 2010, Zurich, Switzerland
NanoBio - Zurich 2010

Latest Press Release

Budapest, Hungary, 11 Janurary 2011
NanGenex successfully validated its latest GMP compliant industrial scale NanoPilot™ instrument

Nangenex Inc. has successfully completed the chemical validation of its lates GMP compliant pilot plant reactor. This is the first milestone towards fulfillin production needs of the clinical development of NanGenex's NanoActive™ products.

Budapest, Hungary, 31 August 2010
NanGenex to introduce the new GMP compliant industrial scale NanoPilot™ instrument

Nangenex Inc., the Proprietary NanoSolution Technology Platform Company presents its latest GMP compliant benchtop and pilot pant reactor for the industrial scale production of NanoActive™ nanoparticles.

Read this article

See the intsruments

Budapest, Hungary, 27 July 2010
In vivo data confirms effectiveness of the NanoActive™ technology in imrpoving bioavailability

Budapest, Hungary - Nangenex Inc., the proprietary NanoActive™ continuous flow technology platform company has completed the first round in vivo testing of NanoActive™ nanoformulations of blockbuster drugs.

Budapest, Hungary, 13 April 2010
NanoForm Cardiovascular Therapeutics Ltd, London, UK established for the further development and commercialization of proprietary NanoActive™ formulations of two blockbuster drugs for cardiovascular indications.

Budapest, Hungary, 12 October 2009
ThalesNano signs strategic alliance with NanGenex to offer revolutionary nanosizing continuous flow technology service.

Budapest, Hungary, 03 September 2009
Proprietary continuous flow NanoActive™ technology to formulate nanosized active molecules from NanGenex.

Papers

MST News, 2008, 3(8), 30-31
Niesz, K.; Wootsch, A.; Otvos, Zs.; Darvas, F.
Synthesis of Nanostructures on a Microfluidic-based Flow Device

Microfluidics and Nanofluidics, 2008, 1613-4982
Niesz, K., Hornyak, I., Borcsek, B., Darvas, F.
Nanoparticle synthesis completed with in situ catalyst preparation performed on a high-pressure high-temperature continuous flow reactor